Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

A Novel Excipient, 1-perfluorohexyloctane Shows Limited Utility For The Oral Delivery Of Poorly Water-soluble Drugs.

R. Holm, E. B. Jørgensen, Michael Harborg, R. Larsen, P. Holm, A. Müllertz, J. Jacobsen
Published 2011 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The applicability of the semi-fluorinated alkane 1-perfluorohexyloctane (F6H8) as a novel excipient in lipid based drug delivery systems was studied. Solubility studies of 11 poorly water soluble drugs (cinnarizine, danazol, estradiol, fenofibrate, griseofulvin, halofantrine, lidocaine, prednisolone, probucol, rolipram and siramesine) showed significantly lower equilibrium solubility in F6H8 compared to soy bean oil (long chain triglyceride). F6H8 was miscible with medium chain triglycerides (MCT) but not miscible with long chain triglycerides, neither was pure F6H8 nor the mixture F6H8:MCT (1:1) miscible with 7 commonly used surfactants (Cremophor EL, Span 20, Span 80, Labrasol, Softigen 767 and Gelucire 44/14, polysorbate 80). In vitro lipolysis studies confirmed that F6H8 was non-digestible. F6H8:MCT (1:1) showed initially faster lipolysis compared to pure MCT. Thus, final phase lipolysis was lower indicating that F6H8 may affect the lipolysis of MCT. However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml). Generally, the addition of polysorbate 80 shortened the time to reach C(max) (T(max) ranged 1.3-4.5h), but had limited effect on the bioavailability from F6H8 or MCT in combination with polysorbate 80 (4:1) (AUC ranged from 3807 to 4403 (hng/ml)). Although a synergistic effect was obtained with halofantrine in F6H8:MCT:polysorbate 80 (2:2:1) (AUC 5574±675hng/ml; mean±SEM), it was not superior to dosing halofantrine in pure polysorbarte 80 (AUC 7370±579hng/ml; mean±SEM). The applicability of F6H8 as an excipient for future use in lipid based formulations for poorly water soluble drugs is therefore considered to be very limited.
This paper references
10.1023/A:1020311127328
Structured Triglyceride Vehicles for Oral Delivery of Halofantrine: Examination of Intestinal Lymphatic Transport and Bioavailability in Conscious Rats
R. Holm (2004)
10.1016/J.CHEMOSPHERE.2005.03.084
An overview of environmental hazards and exposure risk of hydrofluorocarbons (HFCs).
W. Tsai (2005)
10.1016/S0040-4020(02)00262-4
Fluorous micro- and nanophases with a biomedical perspective
J. Riess (2002)
10.1517/17425247.4.4.403
Drug delivery strategies for poorly water-soluble drugs
A. Fahr (2007)
10.1016/J.BIOPHA.2004.02.001
Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs.
R. N. Gursoy (2004)
10.1016/S0169-409X(01)00107-7
Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research.
M. Krafft (2001)
10.1016/S1359-0294(03)00045-1
Emulsions and microemulsions with a fluorocarbon phase
M. Krafft (2003)
10.1248/BPB.29.508
Disposition of lipid-based formulation in the intestinal tract affects the absorption of poorly water-soluble drugs.
K. Iwanaga (2006)
10.1248/CPB.38.2792
Gastro-intestinal absorption of ethyl 2-chloro-3-[4-(2-methyl-2-phenylpropyloxy)phenyl]propionate from different dosage forms in rats and dogs.
H. Toguchi (1990)
10.1248/CPB.38.2797
Effects of the physicochemical properties of the emulsion formulation on the bioavailability of ethyl 2-chloro-3-[4-(2-methyl-2-phenylpropyloxy)phenyl]propionate in rats.
H. Toguchi (1990)
10.1023/B:PHAM.0000016282.77887.1f
Drug Solubilization Behavior During in Vitro Digestion of Simple Triglyceride Lipid Solution Formulations
A. Kaukonen (2004)
10.1038/242337A0
Toxicology of Fluoro-olefins
E. Cook (1973)
10.1007/978-1-4615-2468-7_30
Novel fluorocarbon-based injectable oxygen-carrying formulations with long-term room-temperature storage stability.
J. Riess (1994)
10.1016/S0378-5173(97)00325-6
Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A
Z. Gao (1998)
10.1007/S004670100580
Erratum: Reduced variability of neoral pharmacokinetic studies in pediatric renal transplantation (Pediatric Nephrol (2000) vol. 15 (2-6))
R. Portman (2001)
10.1016/S0928-0987(01)00169-5
A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium.
N. H. Zangenberg (2001)
Effects of tauroursodeoxycholate solutions on cyclosporin A bioavailability in rats.
N. Balandraud-Pieri (1997)
10.1023/A:1018914215345
Biodistribution of Mixed Fluorocarbon–Hydrocarbon Dowel Molecules Used as Stabilizers of Fluorocarbon Emulsions: A Quantitative Study by Fluorine Nuclear Magnetic Resonance (NMR)
L. Zarif (2004)
10.1016/S1359-0294(03)00052-9
Aggregates from semifluorinated n-alkanes: how incompatibility determines self-assembly
P. L. Nostro (2003)
10.1021/JA00231A034
Semifluorinated hydrocarbons: primitive surfactant molecules
M. Turberg (1988)
10.1002/1520-6017(200008)89:8<1073::AID-JPS12>3.0.CO;2-V
Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats.
S. Caliph (2000)
10.1021/JS9502229
Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion.
C. J. Porter (1996)
10.1016/S0169-409X(00)00129-0
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
C. Lipinski (1997)
10.1002/JPS.21246
Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs.
Jean F Cuiné (2008)
10.1016/0014-2999(76)90318-6
Fenfluramine: long-term reduction in brain serotonin (5-hydroxytryptamine).
B. V. Clineschmidt (1976)
10.1016/S0039-6257(05)80093-1
Perfluorocarbon liquids in ophthalmology.
G. Peyman (1995)
10.1002/ADMA.19910030507
Highly effective surfactants with low hemolytic activity
J. Riess (1991)
10.1002/ANIE.199619761
Achieving Stable, Reverse Water‐in‐Fluorocarbon Emulsions
Vérpnique M. Sadtler (1996)
10.1016/J.ADDR.2007.05.006
Oral lipid-based formulations.
D. Hauss (2007)
10.1021/CR970143C
Oxygen Carriers (“Blood Substitutes”)Raison d'Etre, Chemistry, and Some Physiology Blut ist ein ganz besondrer Saft1
J. Riess (2001)
10.1016/0731-7085(95)01256-K
A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions.
A. Humberstone (1995)
10.1016/J.EJPS.2004.08.003
Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols.
J. Christensen (2004)
10.1007/s004170100264
Combined use of partially fluorinated alkanes, perfluorocarbon liquids and silicone oil: an experimental study
H. Hoerauf (2001)
10.1002/ANIE.199411001
Stable Highly Concentrated Fluorocarbon Gels
Marie-Pierre Krafft (1994)
10.1007/s11095-004-7684-4
Stimulation of Triglyceride-Rich Lipoprotein Secretion by Polysorbate 80: In Vitro and in Vivo Correlation Using Caco-2 Cells and a Cannulated Rat Intestinal Lymphatic Model
Fergal Seeballuck (2004)
10.1016/S0928-0987(01)00182-8
A dynamic in vitro lipolysis model. II: Evaluation of the model.
N. H. Zangenberg (2001)
10.1080/10915810600961531
Nonclinical Vehicle Use in Studies by Multiple Routes in Multiple Species
S. Gad (2006)
10.1177/1087057109335677
Applications of Adaptive Focused Acoustics to Compound Management
E. Nixon (2009)
10.1211/0022357021771896
Evaluation of the in‐vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products
L. Sek (2002)
10.1016/j.ejpb.2007.12.020
Bioavailability of probucol from lipid and surfactant based formulations in minipigs: influence of droplet size and dietary state.
F. S. Nielsen (2008)
10.1021/J100785A001
van der Waals Volumes and Radii
A. Bondi (1964)
10.1016/0022-1139(96)03415-X
Characterization of the lipophilicity of fluorocarbon derivatives containing halogens or hydrocarbon blocks
T. Le (1996)
10.1007/s004670000435
Reduced variability of Neoral pharmacokinetic studies in pediatric renal transplantation
R. Portman (2000)
The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine.
D. Holt (1994)
10.1021/cr800260k
Chemistry, physical chemistry, and uses of molecular fluorocarbon--hydrocarbon diblocks, triblocks, and related compounds--unique "apolar" components for self-assembled colloid and interface engineering.
M. Krafft (2009)
10.1007/978-3-0348-6513-5
Modern Trends of Colloid Science in Chemistry and Biology
Hans-Friedrich Eicke (1985)
10.1007/s11095-008-9641-0
Lipid-based Formulations for Danazol Containing a Digestible Surfactant, Labrafil M2125CS: In Vivo Bioavailability and Dynamic In Vitro Lipolysis
A. Larsen (2008)
10.1211/jpp.62.01.0006
Effects of polysorbate 80 on the in‐vitro precipitation and oral bioavailability of halofantrine from polyethylene glycol 400 formulations in rats
H. Tønsberg (2010)
10.1021/JA00163A065
Are fluorocarbon chains stiffer than hydrocarbon chains? Dynamics of end-to-end cyclization in a C8F16 segment monitored by fluorescence
D. F. Eaton (1990)
10.1016/J.CIS.2007.11.002
Semifluorinated alkanes--primitive surfactants of fascinating properties.
M. Broniatowski (2008)
10.1016/S0142-9612(99)00220-3
Biomaterials used in the posterior segment of the eye.
M. Colthurst (2000)
10.1016/J.COLSURFB.2005.11.022
Characterization of phospholipid+semifluorinated alkane vesicle system.
J. Sabín (2006)
10.1016/J.IJPHARM.2003.10.036
Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility.
P. C. de Smidt (2004)
10.1080/01932699008943243
A NEW FORMULATION FOR BLOOD SUBSTITUTES
C. Cecutti (1990)
10.1016/j.ejps.2008.07.003
Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80.
Marianne L Lind (2008)
10.2133/DMPK.20.244
The novel formulation design of self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion I: enhancing effects on oral bioavailability of poorly water soluble compounds in rats and beagle dogs.
H. Araya (2005)



This paper is referenced by
10.3109/03639045.2012.710634
Optimization of self nanoemulsifying drug delivery system for poorly water-soluble drug using response surface methodology
S. Ren (2013)
Pharmaceutical Preformulation Studies - Current Review
R. Gopinath (2011)
Évaluation d'une forme galénique à base d'alpha cyclodextrine et d'huile végétale pour l'administration par voie orale de molécules actives peu solubles dans l'eau
M. Hamoudi (2012)
From Molecule to Dose Form – Accelerated Bioavailability Enhancement for Early Phase Molecules
Jean-Luc Veuthey (2015)
10.1016/j.ejpb.2013.06.013
Buccal absorption of propofol when dosed in 1-perfluorobutylpentane to anaesthetised and conscious Wistar rats and Göttingen mini-pigs.
C. Tsagogiorgas (2013)
10.1016/j.ejpb.2012.03.005
Influence of bile on the absorption of halofantrine from lipid-based formulations.
R. Holm (2012)
10.1177/2472630318820017
Next-Generation Compound Delivery Platforms to Support Miniaturized Biology
S. Bhatt (2019)
10.1016/S1773-2247(13)50054-2
Recent developments in oral lipid-based drug delivery
Nicky Thomas (2013)
10.1016/j.ejps.2012.06.007
Using resin to generate a non-invasive intestinal bile-depleted rat model was unsuccessful.
R. Holm (2012)
10.1016/j.ijpharm.2017.06.040
The role of lecithin degradation on the pH dependent stability of halofantrine encapsulated fat nano-emulsions.
Iman Haidar (2017)
10.1016/J.JCT.2016.10.032
Semifluorinated alkanes and alkanes : a phase study of the perfluorohexyloctane - tetradecane system
Anna Runnsjö (2017)
10.1016/j.ejpb.2014.08.006
In vitro-in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623.
Claire L McEvoy (2014)
Technical Report : Improvement of Dissolution Properties of Ketoconazole Using a New Excipient ( LoxOral ® ) in Comparison with Microcrystalline Cellulose
(2017)
10.1016/j.jconrel.2012.02.027
In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS).
N. Thomas (2012)
10.5451/UNIBAS-005750236
Evaluation of lipid-based formulations of poorly water-soluble drugs in the gastro-intestinal tract using in vitro tests
Y. E. Arnold (2011)
10.1016/j.xphs.2019.01.021
Physical Characterization of Halofantrine-Encapsulated Fat Nanoemulsions.
Iman Haidar (2019)
10.1016/J.COLSURFA.2016.01.012
Emulsions of fluorinated oils stabilised by fluorinated silica nanoparticles
I. E. Salama (2016)
Semantic Scholar Logo Some data provided by SemanticScholar